Leucid Bio

Leucid Bio is a UK-based biotechnology startup founded in 2014, with a focus on developing Autologous and Allogeneic cell and gene Therapies for hard-to-treat cancers. The company's slogan, "Thinking laterally about CAR-T," reflects its innovative approach to progressing novel CAR T therapies that aim to produce a better and more durable response than previous generations. This innovation promises to improve treatment outcomes and save the lives of patients with refractory cancers. In its latest funding round, Leucid Bio raised a significant £11.50M in a Series A investment on 21 October 2021. The investors in this round included prominent names such as Sofinnova Partners, Vulpes Investment Management, Epidarex Capital, British Business Bank, and 2invest. These investments serve as a testament to the confidence that industry leaders have in the potential of Leucid Bio's innovative approach to CAR T therapies. Overall, Leucid Bio's dedication to pushing the boundaries of CAR T therapy and its ability to attract substantial investments from reputable sources such as Sofinnova Partners and Epidarex Capital position it as a noteworthy player in the biotechnology and healthcare industries. This demonstrates the company's potential to make a lasting impact on the treatment of challenging cancers, making it an intriguing prospect for venture capital investors seeking opportunities in the life sciences sector.